Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
44
KZR Quote, Financials, Valuation and Earnings
Last price:
$6.23
Seasonality move
:
-4.23%
Day range:
$6.13 - $6.25
52-week range:
$3.53 - $7.25
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.55x
Volume:
23.6K
Avg. volume:
51.8K
1-year change:
-11.35%
Market cap:
$45.8M
Revenue:
--
EPS (TTM):
-$8.44
Analysts' Opinion
-
Consensus RatingKezar Life Sciences, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $6.00, Kezar Life Sciences, Inc. has an estimated downside of -4% from its current price of $6.25.
-
Price Target UpsideAccording to analysts, the highest upside price target is $7.00 representing -100% upside increase from its current price of $6.25.
Fair Value
-
According to the consensus of 4 analysts, Kezar Life Sciences, Inc. has -4% downside to fair value with a price target of $6.00 per share.
KZR vs. S&P 500
-
Over the past 5 trading days, Kezar Life Sciences, Inc. has overperformed the S&P 500 by 0.69% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Kezar Life Sciences, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Kezar Life Sciences, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Kezar Life Sciences, Inc. reported revenues of --.
Earnings Growth
-
Kezar Life Sciences, Inc. has grown year-over-year earnings for 7 quarters straight. In the most recent quarter Kezar Life Sciences, Inc. reported earnings per share of -$1.53.
Enterprise value:
-34.5M
EV / Invested capital:
-0.37x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.61x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$980K
Return On Assets:
-48.14%
Net Income Margin (TTM):
--
Return On Equity:
-58.35%
Return On Invested Capital:
-51.59%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $7M | -- | -- | -- | -- | |
| Gross Profit | $6.2M | -$1.1M | -$980K | -$260K | -$227K | |
| Operating Income | -$96.9M | -$96M | -$65.5M | -$21.9M | -$11.7M | |
| EBITDA | -$96.4M | -$94.9M | -$64.5M | -$21.7M | -$11.5M | |
| Diluted EPS | -$12.12 | -$13.15 | -$8.44 | -$2.78 | -$1.53 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $124.8M | $298.9M | $230.5M | $156.4M | $94.5M | |
| Total Assets | $130.9M | $304.8M | $249.3M | $164.1M | $97.7M | |
| Current Liabilities | $7.9M | $9.6M | $16.7M | $20.4M | $13.4M | |
| Total Liabilities | $11.4M | $21.6M | $33.3M | $30M | $14.8M | |
| Total Equity | $119.5M | $283.2M | $216M | $134M | $83M | |
| Total Debt | $4.7M | $12M | $16.7M | $13.5M | $6.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$78.5M | -$76.4M | -$56.6M | -$17.5M | -$9.8M | |
| Cash From Investing | $39.5M | $84.6M | $64.6M | $24.1M | $15.7M | |
| Cash From Financing | $1.1M | $115K | -$3.8M | -- | -$1.3M | |
| Free Cash Flow | -$80.7M | -$76.4M | -$56.7M | -$17.5M | -$9.8M | |
KZR
Sector
Market Cap
$45.8M
$28.4M
Price % of 52-Week High
86.21%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
5.1%
-1.32%
1-Year Price Total Return
-11.35%
-22.19%
Beta (5-Year)
0.505
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$6.22
200-day SMA
Buy
Level
$4.75
Bollinger Bands (100)
Buy
Level
3.73 - 5.81
Chaikin Money Flow
Sell
Level
-5.4M
20-day SMA
Buy
Level
$6.19
Relative Strength Index (RSI14)
Buy
Level
64.14
ADX Line
Buy
Level
27.4
Williams %R
Neutral
Level
-20
50-day SMA
Buy
Level
$5.50
MACD (12, 26)
Buy
Level
0.16
25-day Aroon Oscillator
Buy
Level
28
On Balance Volume
Neutral
Level
12M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.2051)
Sell
CA Score
(Annual)
Level (-1.1373)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (5.0927)
Sell
Piotroski F Score
(Annual)
Level (2)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer. Its product pipeline includes KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 19, 2015 and is headquartered in South San Francisco, CA.
Stock Forecast FAQ
In the current month, KZR has received 0 Buy ratings 4 Hold ratings, and 0 Sell ratings. The KZR average analyst price target in the past 3 months is $6.00.
-
Where Will Kezar Life Sciences, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Kezar Life Sciences, Inc. share price will drop to $6.00 per share over the next 12 months.
-
What Do Analysts Say About Kezar Life Sciences, Inc.?
Analysts are divided on their view about Kezar Life Sciences, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Kezar Life Sciences, Inc. is a Sell and believe this share price will rise from its current level to $5.00.
-
What Is Kezar Life Sciences, Inc.'s Price Target?
The price target for Kezar Life Sciences, Inc. over the next 1-year time period is forecast to be $6.00 according to 4 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is KZR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Kezar Life Sciences, Inc. is a Hold. 4 of 4 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of KZR?
You can purchase shares of Kezar Life Sciences, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Kezar Life Sciences, Inc. shares.
-
What Is The Kezar Life Sciences, Inc. Share Price Today?
Kezar Life Sciences, Inc. was last trading at $6.23 per share. This represents the most recent stock quote for Kezar Life Sciences, Inc.. Yesterday, Kezar Life Sciences, Inc. closed at $6.25 per share.
-
How To Buy Kezar Life Sciences, Inc. Stock Online?
In order to purchase Kezar Life Sciences, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get KZR Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
KZR
Sector
P/E ratio
--
23.66x
PEG ratio
--
-0.01x
P/B ratio
0.55x
1.84x
Price / LTM sales
--
1.60x
Growth Metrics
KZR
Sector
Revenue growth
--
4.85%
Earnings growth
44.93%
11.15%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$1.96
-$0.20
Profitability
KZR
Sector
Profitability FY 2024
-$1M
$3.6M
Return on invested capital
-51.59%
-30.98%
Return on assets
-48.14%
-27.62%
Return on equity
-58.35%
-36.69%
Earnings Date
Last Earnings Date
Nov
12
Next Earnings Date
Mar
31
Estimated Next Earnings Date
Feb
11
Balance Sheet
KZR
Sector
Total cash
$90.2M
$27.2M
Short term investments
$90.5M
$25.7M
Total assets
$144.7M
$79.9M
Long term debt
$6.7M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 18.9% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
